Checkpoint Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Checkpoint Therapeutics

01/11/2022 02:07

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $15​, above​ its last closing price
of $1.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.18       -0.17      -0.16     Beat    7.2
 Mar. 31 2022  -0.14       -0.14      -0.20     Missed  -40.8
 Dec. 31 2021  -0.15       -0.15      -0.39     Missed  -153.2
                                                        ​
 Sep. 30 2021  -0.13       -0.14      -0.14     Met     -2.9
 ​​Jun.        -0.10       -0.10      -0.12     Missed  -15.4
 30 2021                                                
 Mar. 31 2021  -0.11       -0.10      -0.09     Beat    14.3​
 Dec. 31 2020  -0.08       -0.08      -0.17     Missed  -112.5
 Sep. 30 2020  -0.08       -0.08      -0.09     Missed  -12.5
 This summary was machine generated November 1 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated